Investment Firm Downgrades Cepheid to Sell | GenomeWeb

NEW YORK (GenomeWeb News) – Investment firm ISI Group today downgraded shares of Cepheid to Sell, saying it expects the Sunnyvale, Calif. molecular diagnostics firm's base business to slow due to increased competition in the hospital-acquired infection space.

In a research note, analyst Vijay Kumar put Cepheid's price target at $34 per share and outlined three factors that he expects to constrain the company's growth in the medium term. They include competition in the HAI space; limited upside to the company's new products; and pricing pressures and higher cost of goods sold.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.